The aim of this study is to lay the bases for an ambitious project that reports and records all the epidemiological-clinical information of the cases of endometrial carcinoma diagnosed and treated in the reference oncology centers involved on the national territory, to create a process of analysis of the data
diagnosis of endometrial cancer (stage I-IV, G1-3, and special histotypes)
age > 18 years
American Society of Anesthesiologists classification (ASA score) 1-3
patients undergoing staging, cytoreduction or diagnostic surgery with acquisition of histological examination on which IHC and/or NGS studies have been performed for the molecular profile of the carcinoma
patients with missing information
patients not treated in the participating centers for which only partial and fragmented information will be available
molecular profile not known and\or not recoverable and retrospectively analysable
All patients undergoing staging and cytoreduction surgery for endometrial cancer will be included in the study. This database will make use of data collected retrospectively with prospectively continuously updated prognostic and clinical information. The following data will be collected: clinical characteristics (age, BMI, ASA, previous tumors), histopathological data (histotype, grade, FIGO stage, etc.) Furthermore, data will be collected relating to the adjuvant chemotherapy or radiotherapy treatment performed, survival outcome (DFS and OS), number of relapses and deaths, type of relapse, treatment at relapse, cause of death.
Cohort
Cross-sectional
Not listed
Disease Free Survival
To evaluate the impact of the immuno-molecular and clinical profile of endometrial cancer on the outcomes of DFS (Disease-Free Survival).
Overall Survival
To evaluate the impact of the immuno-molecular and clinical profile of endometrial cancer on the outcomes of OS (overall survival).
Click on the lead sponsor to view all of their trials.
